SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Salt Lake City, March 22, 2018 -- SelectHealth has signed a value-based contract with Novo Nordisk, a leader in diabetes care, to measure outcomes among patients with type 2 diabetes using Victoza® (liraglutide). Victoza may improve blood sugar in adults with type 2 diabetes when used in conjunction with diet and exercise.
|
|||
Both SelectHealth and Novo Nordisk will track metrics built into the contract designed to measure and understand how members use Victoza and how it supports their diabetes and overall healthcare goals.
Eric Cannon, SelectHealth Pharmacy Benefit Services AVP, said “Diabetes is a significant driver of cost. We are excited to enter into an agreement that is focused on improving clinical outcomes and providing value to our members. SelectHealth and Intermountain Healthcare will continue to explore value-based opportunities that improve health and value for our members.”
“Due to the costs associated with unmanaged diabetes and its increasing prevalence in the US, value-based contracting can help us learn more about how our medicines can improve patients’ lives,” said Todd Hobbs, MD, chief medical officer, Novo Nordisk Inc. “We stand behind the clinical value of our medicines, and consider this contract an exciting opportunity to not only showcase this efficacy, but also to improve access for patients.”
###
SelectHealth is a not-for-profit health plan that serves more than 850,000 members in Utah and Idaho. Through a shared mission with Intermountain Healthcare of Helping People Live the Healthiest Lives Possible®, we are committed to assuring access to high-value care, providing superior service, and supporting the health of our members and the communities we serve.
In addition to medical plans, SelectHealth offers dental, vision, pharmacy benefit management, and life and disability coverage to its members. SelectHealth plans are available for Medicare Advantage and Medicaid enrollees, and we’re also a carrier for the Children’s Health Insurance Plan (CHIP) and the Federal Employee Health Benefits (FEHB) Plan.
Year-after-year, SelectHealth is rated as Utah’s top HMO plan by state and national organizations, receiving top scores in both member satisfaction and clinical performance. For details, visit selecthealth.org.
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bc6f12a7-a775-43ce-8a3f-221a70b893c1
SelectHealth Media SelectHealth 801-442-7962 [email protected]
